Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind comparison of an MDCK cell-based quadrivalent split influenza vaccine in people aged 3 years and older
CTR20233159Phase 3Completed
- Sponsor
- Wuhan Institute of Biological Products
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of MDCK cell-based quadrivalent split influenza vaccine in influenza, sponsored by Wuhan Institute of Biological Products. Started Sep 2023; status: completed.
02
Drugs
MDCK cell-based quadrivalent split influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on CTR20233159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233159.